Our Five Best-Performing Stocks Since the December Monthly Meeting Are Tech-Free
It's been a topsy-turvy start to 2025 for the stock market. Since the Club's monthly meeting in December, Wall Street…
investment strategy
Strategas sees healthcare outperforming in 2025
The healthcare sector is poised to see a rebound and lead the market this year, according to analysts at Strategas,…
Stocks rise on cold inflation, hot bank profits and new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
How much can you save if you don't drink for a month?
Ryanjlane | E+ | fake images The beginning of a new year is the most popular time to make a…
Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
CFPB sues JPMorgan Chase, Bank of America and Wells Fargo over Zelle fraud
Rohit Chopra, Director of the CFPB, testifies during the Senate Committee on Banking, Housing and Urban Affairs hearing titled “Semi-Annual…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…